(Q57991024)

Pedro A. Fernandes

4

0 references

Maria J. Ramos

Maria J. Ramos

Nuno M. F. S. A. Cerqueira

3

0 references

2

N.S. Hari Narayana Moorthy

Nuno S. Cerqueira

0 references

1

Medicinal Chemistry Research

N. S. Hari Narayana Moorthy

0 references

publication date

2 December 2010

0 references

published in

0 references

volume

21

0 references

issue

2

0 references

page(s)

133-144

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s00044-010-9510-3

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

QSAR modelling of HIV-1 reverse transcriptase inhibition by benzoxazinones using a combination of P_VSA and pharmacophore feature descriptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumour therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

Enzyme Ribonucleotide Reductase: Unraveling an Enigmatic Paradigm of Enzyme Inhibition by Furanone Derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

Understanding ribonucleotide reductase inactivation by gemcitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

Influential Observations in Linear Regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

VolSurf: a new tool for the pharmacokinetic optimization of lead compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

Inhibition of herpes simplex virus type 1 and adenovirus type 5 by heterocyclic Schiff bases of aminohydroxyguanidine tosylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

TESTING FOR SERIAL CORRELATION IN LEAST SQUARES REGRESSION. II

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

Synthesis, structure-activity relationships, and antitumor studies of 2-benzoxazolyl hydrazones derived from alpha-(N)-acyl heteroaromatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

Methods for reliability and uncertainty assessment and for applicability evaluations of classification- and regression-based QSARs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

Theoretical studies on the mechanism of inhibition of Ribonucleotide Reductase by (E)-2'-Fluoromethylene-2'-deoxycitidine-5'-diphosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

Structure, function, and mechanism of ribonucleotide reductases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

A New Electroaffinity Scale; Together with Data on Valence States and on Valence Ionization Potentials and Electron Affinities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

Hydroxyurea: new insights on an old drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

Ribonucleotide reductases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

QSAR analyses of conformationally restricted 1,5-diaryl pyrazoles as selective COX-2 inhibitors: application of connection table representation of ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

Understanding the antitumor activity of novel hydroxysemicarbazide derivatives as ribonucleotide reductase inhibitors using CoMFA and CoMSIA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

Synthesis, biological evaluation, and quantitative structure-activity relationship analysis of new Schiff bases of hydroxysemicarbazide as potential antitumor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

A Caution Regarding Rules of Thumb for Variance Inflation Factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

Ribonucleotide reductase inhibitors and future drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

The enzyme ribonucleotide reductase: target for antitumor and anti-HIV therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

Rational polynomial representation of ribonucleotide reductase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

The Importance of Being Earnest: Validation is the Absolute Essential for Successful Application and Interpretation of QSPR Models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3

Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9510-3